StockNews.AI
CGEM
StockNews.AI
4 hrs

Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum

1. Jeffrey Jones, CMO, will speak at the Stifel Immunology Forum. 2. Cullinan Therapeutics focuses on targeted therapies for autoimmune diseases and cancer. 3. Company emphasizes a diversified portfolio and innovative therapeutic solutions.

4m saved
Insight
Article

FAQ

Why Bullish?

The upcoming discussion can enhance investor confidence, driving interest in CGEM stock.

How important is it?

Discussion by a high-level executive at a significant forum could positively influence CGEM's market perception.

Why Short Term?

Immediate market reaction expected from the forum's insights and announcements.

Related Companies

VRTXBMYAMGN
September 12, 2025 07:00 ET  | Source: Cullinan Therapeutics, Inc. CAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum on Tuesday, September 16, 2025, at 9:30 a.m. ET. A webcast of the fireside chat will be available under the Events and Presentations section of the Company’s investor relations website at https://investors.cullinantherapeutics.com/events. About Cullinan Therapeutics Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company dedicated to creating new standards of care for patients. Cullinan has strategically built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both autoimmune diseases and cancer. Cullinan’s portfolio encompasses a wide range of modalities, each with the potential to be best and/or first in class. Anchored in a deep understanding of oncology, immunology, and translational medicine, we create differentiated ideas, identify the most appropriate targets, and select the optimal modality to develop transformative therapeutics across a wide variety of autoimmune and cancer indications. We push conventional boundaries from candidate selection to differentiated therapeutic, applying rigorous go/no go criteria at each stage of development to fast-track only the most promising molecules to the clinic and, ultimately, commercialization. With deep scientific expertise, our teams exercise creativity and urgency to deliver on our promise to bring new therapeutic solutions to patients. Learn more about Cullinan at https://cullinantherapeutics.com/, and follow us on LinkedIn and X. Contacts: Investor RelationsNick Smith+1 401.241.3516nsmith@cullinantx.com MediaRose Weldon+1 215.801.7644rweldon@cullinantx.com

Related News